S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Get Your Cash Out of U.S. Banks Immediately (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Get Your Cash Out of U.S. Banks Immediately (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Get Your Cash Out of U.S. Banks Immediately (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Get Your Cash Out of U.S. Banks Immediately (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio

DBV Technologies (DBVT) Stock Forecast, Price & News

$1.30
0.00 (0.00%)
(As of 09/27/2023 ET)
Compare
Today's Range
$1.29
$1.33
50-Day Range
$1.30
$1.75
52-Week Range
$1.08
$2.37
Volume
8,170 shs
Average Volume
127,270 shs
Market Capitalization
$250.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

DBV Technologies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
438.5% Upside
$7.00 Price Target
Short Interest
Bearish
0.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$42,540 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.54) to ($0.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

705th out of 976 stocks

Biological Products, Except Diagnostic Industry

110th out of 158 stocks


DBVT stock logo

About DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBVT Price History

DBVT Stock News Headlines

Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
DBV.PA - DBV Technologies S.A.
Pentagon Consultant—Here's how Biden Wins Landslide Re-election
—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,
DBV.F - DBV Technologies S.A.
DBVT - DBV Technologies S.A.
See More Headlines
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Company Calendar

Last Earnings
7/31/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DBVT
Employees
88
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+438.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-96,270,000.00
Pretax Margin
-1,929.49%

Debt

Sales & Book Value

Annual Sales
$4.84 million
Book Value
$1.03 per share

Miscellaneous

Free Float
191,347,000
Market Cap
$250.25 million
Optionable
Optionable
Beta
1.17
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Daniel Tassé (Age 63)
    CEO & Director
    Comp: $1.21M
  • Mr. Sébastien Robitaille (Age 53)
    Chief Financial Officer
    Comp: $335.17k
  • Dr. Pharis Mohideen (Age 58)
    Chief Medical Officer
    Comp: $725.12k
  • Mr. Pascal Wotling
    Chief Technical Operations Officer & Chief Quality Officer
  • Ms. Michele F. Robertson
    Chief Legal Officer
  • Joseph Becker
    VP of Global Corp. Communications
  • Ms. Caroline Daniere (Age 48)
    Chief HR Officer & Chief of Staff
  • Dr. Wence Agbotounou
    Chief Clinical Trial Officer & Sr. VP
  • Mr. Edward P. Jordan M.B.A. (Age 55)
    Sr. VP of Commercial Operations North America
  • Alan Kerr
    Sr. VP & Head of Global Regulatory Affairs













DBVT Stock - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DBVT shares.
View DBVT analyst ratings
or view top-rated stocks.

What is DBV Technologies' stock price forecast for 2023?

4 analysts have issued 1 year target prices for DBV Technologies' stock. Their DBVT share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 438.5% from the stock's current price.
View analysts price targets for DBVT
or view top-rated stocks among Wall Street analysts.

How have DBVT shares performed in 2023?

DBV Technologies' stock was trading at $1.53 at the start of the year. Since then, DBVT shares have decreased by 15.0% and is now trading at $1.30.
View the best growth stocks for 2023 here
.

When is DBV Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DBVT earnings forecast
.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Monday, July, 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $2.29 million for the quarter, compared to analysts' expectations of $1 million.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?

DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."

Who are DBV Technologies' major shareholders?

DBV Technologies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (1.62%), BlackRock Inc. (0.53%), Optiver Holding B.V. (0.02%), BNP Paribas Arbitrage SNC (0.02%), Citadel Advisors LLC (0.02%) and Envestnet Asset Management Inc. (0.01%). Insiders that own company stock include Daniel B Soland, Pharis Mohideen and Timothy E Morris.
View institutional ownership trends
.

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DBV Technologies' stock price today?

One share of DBVT stock can currently be purchased for approximately $1.30.

How much money does DBV Technologies make?

DBV Technologies (NASDAQ:DBVT) has a market capitalization of $250.25 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How can I contact DBV Technologies?

DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83.

This page (NASDAQ:DBVT) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -